Imagine if a common healthcare-associated infection became impossible to treat. The nightmare scenario public health officials are contemplating is that an emerging strain of multidrug-resistant Candida auris will displace treatable strains of Candida, which are already a leading cause of bloodstream infections.
A combination of public health, antibiotic stewardship, and infection control efforts over the last six years have managed to beat back the devil of multidrug-resistant bacteria. Yet all still hangs in the balance.
In an experimental study, investigators found cigarette smoke increases the virulence of Staphylococcus aureus strains through several mechanisms, including augmented biofilm formation, increased invasion ability, and persistence within bronchial alveolar cells.
Challenges remain, but programs in place at most hospitals
September 18, 2019
Infection preventionists (IPs) are playing key roles in antibiotic stewardship programs, which are now in place in most U.S. hospitals and making some hard-earned progress against a horde of multidrug-resistant bacteria.
Baloxavir marboxil is a novel, oral, antiviral agent approved by the Food and Drug Administration (FDA) on Oct. 24, 2018, for the treatment of acute uncomplicated influenza in patients 12 years of age and older.